


FIG. 1




1/27

136


2/27

FIG.2




3/27

FIG. 3




4/27

FIG. 4A (Week 3, first challenge)




5/27

FIG. 4B (Week 5, re-challenge)




6/27

FIG. 5A




7/27

FIG. 5B




8/27

FIG. 6




9/27

FIG. 7



10/27

FIG. 8



11/27

FIG.9A




FIG.9B

12/27

FIG. 10A




FIG. 10B




FIG. 11




FIG. 12




FIG. 13





FIG. 14A



18/27

FIG. 14B




FIG. 15A




FIG. 15B




FIG.16A

PEPTIDE →	Ara h	#1	#2	#3	#4	#5	#6	#7	#8	#9	#10
PATIENT 1	5.3	0.9	2.9	3.8	7.8	0.9	0.9	0.7	1	0.9	0.7
PATIENT 2	4.3	0.7	1.4	1.3	2.4	0.9	0.8	0.7	0.7	1	0.7
PATIENT 3	2.8	1	1.8	1.6	2.4	1.1	1.1	1.4	1.7	1.3	1.3
PATIENT 4	1.8	1	0.6	0.8	2.1	1	0.5	0.7	1.4	0.7	0.8
PATIENT 5	5.5	2.1	1.1	0.7	0.8	1	1.3	0.7	1.5	0.5	0.6
PATIENT 6	20.8	1	1.6	2.2	1.7	1.4	1	1.8	2.7	2.6	1.2
PATIENT 7	1.5	0.7	0.5	0.7	0.9	0.9	0.7	0.9	1.1	0.8	0.7
PATIENT 8	6.5	2.4	1.2	1.3	1.1	0.9	1.1	1.4	0.8	0.9	0.8
PATIENT 9	9.2	1.1	1.1	6.3	1.2	1.5	1.2	1	1.2	1.3	0.8
PATIENT 10	11.7	0.7	0.6	0.7	0.6	1.3	0.5	0.6	0.9	0.6	0.5
PATIENT 11	2.1	0.7	0.7	0.5	0.6	0.5	0.3	0.6	0.5	0.5	0.5
PATIENT 12	1.1	1.4	1.6	1.8	2.8	1.5	1.5	1.4	1.3	1.5	1.2
PATIENT 13	0.9	1.3	1.9	1.9	2.8	2	1.6	2.4	1.9	1.5	1.5
PATIENT 14	4.8	1.2	1.6	1.5	1.9	1.6	1.9	1.3	1.6	1.8	1.3
PATIENT 15	6.9	0.7	1.1	1.8	2.1	1.1	1	1.1	1.1	1	0.8
PATIENT 16	10.2	0.7	1.6	2.7	10.9	2	0.9	2.1	2.1	1.4	1
PATIENT 17	4.2	1.4	1.6	2.8	2.6	1.3	1.4	1.7	1.6	1.1	1.3
PATIENT 18	3.9	1.5	1.7	2.9	3	1.5	1.2	1.3	1.3	1.9	1
PATIENT 19	3.4	1.5	1.2	2.6	1.4	1.7	0.9	1	1.4	1.2	1.1

FIG. 16C

#22	#23	#24	#25	#26	#27	#28	#29
6	3.4	4.6	6.4	7.5	5.1	11.3	0.9
3.6	1.4	1.4	1.5	1.9	1.5	2.2	0.5
2.1	1.1	0.7	1.2	1.2	1.3	0.9	1.2
2	1.2	1.1	1.4	1.4	1.5	1.1	0.6
2.5	1.4	1.7	1.9	2.2	1.7	3.3	0.5
0.8	1	0.7	0.9	0.6	0.7	1	1.5
2.3	1.5	1.6	1.3	1.5	1.4	1.8	0.6
1	1.1	1.8	1	1.1	1.5	1.3	1.3
0.5	1.5	1.5	1.2	1.2	1.6	1.1	2
1.3	1.3	0.7	1.5	1.3	1.5	1.4	0.6
0.6	0.6	0.7	0.7	0.8	0.8	0.5	0.5
1.5	1.3	1.3	1.7	1.8	1.1	1.3	1.4
1.6	1.5	1.7	1.6	1.7	2.2	1.3	1.4
1.9	1.6	1.5	2.8	3.3	2	2.7	1.1
1.4	0.9	1.2	1.5	1.5	1.4	1.1	0.9
16.8	1.4	1.7	4.9	3.3	5.3	12.1	1.4
1.7	1.2	1.2	1.9	1.6	1.4	2.9	1.2
7	1.6	1.8	2.7	3.5	4.3	5.1	1.6
2.4	1.4	1.6	1.5	1.3	1.2	1.7	0.9

FROM
FIG. 16B

2042007 0550552

24/27

FIG.17A

Modified Ara h 1:

MASMTGGOMGRDPNSS THAKSSPYQAKT ENPCAQRCLQSCQQEPDALK
QKACESRCKLEYDPRCAYDPRGHTGTTNQRSPPGEATRGRQPGDYDDARRQPRAEEEGGR
WGPAQPREREREEDARQPREDWARPSHQQPRKARPEGREGEQEWGTPGSHVREETSRNNP
FYFPSRRFSTRYGNQNGRI RVLQRFDQRSRQFQNLQNHRI VQIEAKPNTLVLPKHADADN
ILVIQQGQATVTVANGNNRKSFNLDEGHALRIPSGFI SYILNRHDNQNLRVAKISMPVNT
PGQMEDFFPASSRDQSSYLQGFARNTLEAAFNAEANEIRRVLLEENAGGEQEARGQRWS
TRSENNEGVI VKVSKEHVEELTKHAKSVSKKGSEEEGDITNPANLREGEPDLSNNFGKL
AEVKPDKKNPQLQDLDMMLTCVEIKEGALMLPHFNSKAMVIVVNKGTGNLELVAVRKEQ
QQRGRREEEEDEEEEEGSNREVRAYTARLKEGDVFIMPA^hAHPVA INASSELALLGFGIN
AENNHRI FLAGD^hADNVIDQIEKQAKALAA^hPGSGEQVEKL IKNQKESHFVAARPQSQSQSP
SSPEKESPEKEDQEEENQGGKGPLLSILKAFN KLAAALEHHHHHH (SEQ ID NO. 109)

FIG. 17B

Modified Ara h 2:

MASMTGGOMGRDPNS ARQAELQDRRCQSQLARANLRACEAHLMQKI Q
AEDSYERAPYSPSQAPYSPSPYDRRGAGSSQHQERCCNELNEFENNQRC
MCEALQQI MENQSDRLQGAQQEQQFKREARNL PQQCGLRA PQRCDADVES
GGRDRY AAALEHHHHH (SEQ ID NO. 108)

2024-05-23 09:55:00

FIG. 17C

Modified Ara h 3:

M ASFRQQPEENACQFQRLNAQRPDNR IESEGGY IETWNANNQEFECAGV
 ALSRLVLRNALRRPFYSNAPQE IFIQQGRGYFGL IFPGCPRHYEEPHTQGRRSQSQRPP
 RRLQGEDSQQQRDSHQKVHRF DEGDL I AVPTGVAFWL YNDHDTDVVAVSLDTNNNDNQ
 LDQFPRRNFNLAGNTEQEF LRYQQQSQRSSRRSLPSPSPSQSPRQEEREFSRQHSRR
 ERAGQEEENEGGNI FSGFT PEAL FQAFQVDDRQI VQNLRGETESEEEGA I VTVRGGLRAL
 SPDRKRRADEEEYDEDEYAYDEEDRRRGRGRGRNG I EET I CTASAKKN I GRNRSPI
 YNPQAGSLKTANDLNL LILRWLGPSAEYGNLYRNALFVAHYNTNAHSI IYRLRGRAHVQV
 VDSNGNRVYDEELQECHVLVVPQNFVAGKQSENFEYVAFKTDSPSI ANLAGENSVID
 NLPEEVVANSYGLQREQARQLKNNNPFKFVPPSQSPRAVA VDKLAAL EHHHHH

(SEQ ID NO. 110)

Ah2exp3

